A Phase 2, Prospective, Multi-Center, Randomized, Two-Arm, Active Controlled, Double-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of Serum Institute of India 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Indian PCV-Naive Toddlers (12 to 15 months)

Next Previous
Trial Profile

A Phase 2, Prospective, Multi-Center, Randomized, Two-Arm, Active Controlled, Double-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of Serum Institute of India 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Indian PCV-Naive Toddlers (12 to 15 months)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs SIILPCV10 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Sponsors Serum Institute of India

    • Most Recent Events

    • 26 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top